Financial

Year Ended 30 June 2021

• Turnover down 2% to £31.0m (2020: £31.7m)
• Overseas sales up 3% to £19.6m (2020: £19m), representing 63% of total sales (2020: 60%)
• Gross margin remained steady at 80% (2020: 80%)
• Pre-tax profit before share-based payments and adjustment in fair value of investment in Israeli medtech company (£0.8m), down 24% to £5.4m (2020: £7.1m)
• Pre-tax margin before share-based payments and fair value adjustment decreased to 17% (2020: 22%)
• EPS before share-based payments down 34% to 8.16p (2020: 12.35p). Unadjusted down 44% to 6.39p (2020: 11.38p)
• Dividend per share for the full year increased by 6% to 6.55p (2020: 6.18p)
• Strong operating cashflow of £6.5m (2020: £7m)
• Net cash of £8.1m (2020: 6.2m)

To download our Annual Reports, please click on the links below:


To download our interim accounts, please click on the links below: